Known targets — ChEMBL curated mechanism
MTORPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Apitolisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 20/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 14/20 | 1.00 |
| ▸ | MTOR known ✓ | P42345 | 11/20 | 1.00 |
| ▸ | PIK3CB known ✓ | P42338 | 11/20 | 1.00 |
| ▸ | PIK3CG known ✓ | P48736 | 10/20 | 1.00 |
| ▸ | PIK3R1 known ✓ | P27986 | 1/20 | 0.56 |
| ▸ | PIK3C2A | O00443 | 1/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PAK4 | O96013 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | FGR | P09769 | 1/20 | 1.00 |
| ▸ | FER | P16591 | 1/20 | 1.00 |
| ▸ | PRKCA | P17252 | 1/20 | 1.00 |
| ▸ | JAK1 | P23458 | 1/20 | 1.00 |
| ▸ | TEC | P42680 | 1/20 | 1.00 |
| ▸ | SYK | P43405 | 1/20 | 1.00 |
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
| ▸ | MAP3K9 | P80192 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apitolisib SCHEMBL31270275 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| Apitolisib SCHEMBL29447291 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| Apitolisib SCHEMBL1180678 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| Apitolisib SCHEMBL466297 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL1182231 | 0.94 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL1181040 | 0.94 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL1181037 | 0.94 | PIK3CA (1.00) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL11985345 | 0.94 | PIK3CA (0.88) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL1180941 | 0.92 | PIK3CA (0.85) | PIK3CAPIK3CDMTORPIK3CBPIK3CG | |
| SCHEMBL1180938 | 0.92 | PIK3CA (0.85) | PIK3CAPIK3CDMTORPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | claimed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | claimed |
| US-20210186980-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | SOVARGEN CO., LTD. (KR) | 2021-06-24 | — | — | US | claimed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | claimed |
| US-10323228-B2 | Differentiation of hepatocyte-like cells from stem cells | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-06-18 | — | — | US | claimed |
| US-20190070166-A1 | Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease | POSTREL RICHARD (US) | 2019-03-07 | — | — | US | claimed |
| US-20170260503-A1 | DIFFERENTIATION OF HEPATOCYTE-LIKE CELLS FROM STEM CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-09-14 | — | — | US | claimed |
| EP-2518074-B1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | HOFFMANN LA ROCHE (CH) | 2015-07-22 | — | — | EP | claimed |
| EP-2205242-B1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH INC (US) | 2015-04-15 | — | — | EP | claimed |
| US-20110097349-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-28 | — | — | US | claimed |
| US-7888352-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIRAMED LIMITED (GB) | 2011-02-15 | — | — | US | claimed |
| US-20100233164-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH, INC. | 2010-09-16 | — | — | US | claimed |
| WO-2010105008-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH, INC. (US) | 2010-09-16 | — | — | WO | claimed |
| EP-2205242-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | Genentech, Inc. (US) | 2010-07-14 | — | — | EP | claimed |
| EP-2114949-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2009-11-11 | — | — | EP | claimed |
| US-20090098135-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. | 2009-04-16 | — | — | US | claimed |
| WO-2009036082-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2009-03-19 | — | — | WO | claimed |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | US | claimed |
| WO-2008070740-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098135-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | PIK3CA 1/4885PIK3CD 2/4885MTOR 17/4885 |
| US-20100233164-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | PIK3CA, PIK3CD, MCL1 | PIK3CA 1/4885PIK3CD 2/4885MTOR 33/4885 |
| US-20110097349-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | PIK3CA 1/4885PIK3CD 5/4885MTOR 11/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | PIK3CA 2400/4885PIK3CD 3852/4885MTOR 4582/4885 |
| US-20210186980-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | MTOR, MAPKAP1, RPTOR | PIK3CA 358/4885PIK3CD 146/4885MTOR 1/4885 |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | PI4KA, DMPK, PDPK1 | PIK3CA 9/4885PIK3CD 11/4885MTOR 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.